Head-To-Head Survey: Dyadic International (OTCMKTS:DYAI) & Amyris (OTCMKTS:AMRS)

Dyadic International (OTCMKTS:DYAI) and Amyris (NASDAQ:AMRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Institutional & Insider Ownership

0.1% of Dyadic International shares are owned by institutional investors. Comparatively, 34.2% of Amyris shares are owned by institutional investors. 21.8% of Amyris shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Dyadic International and Amyris’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dyadic International N/A N/A N/A
Amyris -255.65% N/A -180.12%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Dyadic International and Amyris, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyadic International 0 0 1 0 3.00
Amyris 0 0 2 0 3.00

Dyadic International currently has a consensus price target of $9.00, suggesting a potential upside of 50.00%. Amyris has a consensus price target of $9.50, suggesting a potential upside of 184.43%. Given Amyris’ higher possible upside, analysts plainly believe Amyris is more favorable than Dyadic International.

Risk and Volatility

Dyadic International has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Amyris has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.

Earnings and Valuation

This table compares Dyadic International and Amyris’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dyadic International $760,000.00 210.89 -$2.14 million ($0.17) -35.29
Amyris $80.42 million 3.18 -$211.35 million ($2.53) -1.32

Dyadic International has higher earnings, but lower revenue than Amyris. Dyadic International is trading at a lower price-to-earnings ratio than Amyris, indicating that it is currently the more affordable of the two stocks.

Summary

Amyris beats Dyadic International on 7 of the 12 factors compared between the two stocks.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corp. to express two therapeutic compounds using C1 production platform; and the Sanofi-Aventis Deutschland GmbH to express the potential of its C1 technology to produce various types of therapeutic compounds for manufacturing protein-based vaccine and biologic drugs; and research collaboration with global biotech company to explore the potential of its C1 technology to produce an active moiety. The company was founded in 1979 and is headquartered in Jupiter, Florida.

About Amyris

Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.